Preliminary studies on the development of IgA-loaded chitosan-dextran sulphate nanoparticles as a potential nasal delivery system for protein antigens

Journal of Microencapsulation

Volumn 30, Issue 3, 2013, Pages 283-294

  Sharma, Sameer ^a,b   Benson, Heather A E ^a   Mukkur, Trilochan K S ^a   Rigby, Paul ^c   Chen, Yan ^a  

^a CURTIN UNIVERSITY   (Australia)

^b CSIRO   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Complex coacervation; M cells; Mucosal delivery; Nanoparticles; Nasopharynx associated lymphoid tissue; Pertussis toxoid; Vaccine

Indexed keywords

ANTIGEN; CHITOSAN; DEXTRAN SULFATE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G ANTIBODY; NANOPARTICLE; PERTUSSIS TOXIN; VACCINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIODEGRADABILITY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DISPERSION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; ISOELECTRIC POINT; MOUSE; NONHUMAN; NOSE MUCOSA; PH; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROCESS OPTIMIZATION; SUSPENSION; ZETA POTENTIAL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS; DEXTRAN SULFATE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULIN A; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES;

EID: 84875028000     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2012.726279     Document Type: Article

References (47)

1. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan- based micro- and nanoparticles in drug delivery. J Control Release, 2004;100: 5-28. (Pubitemid 39445982)
2. Amidi M, Romeijn SG, Borchard G, Junginger HE, Hennink WE, Jiskoot W. Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. J Control Release, 2006;111: 107-16. (Pubitemid 43290000)
3. Amidi M, Romeijn SG, Verhoef JC, Junginger HE, Bungener L, Huckriede A, Crommelin DJA, Jiskoot W. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: Biological properties and immunogenicity in a mouse model. Vaccine, 2007;25: 144-53. (Pubitemid 44855251)
4. Borges O, Cordeiro-da-Silva A, Romeijn SG, Amidi M, de Sousa A, Borchard G, Junginger HE. Uptake studies in rat Peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination. J Control Release, 2006;114: 348-58. (Pubitemid 44310817)
5. Borges O, Tavares J, de Sousa A, Borchard G, Junginger HE, Cordeiro-da- Silva A. Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginatecoated chitosan nanoparticles. Eur J Pharm Sci, 2007;32: 278-90. (Pubitemid 350051890)
6. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine, 2007;25: 5467-84. (Pubitemid 47031365)
7. Brayden DJ, Jepson MA, Baird AW. Keynote review: Intestinal Peyer's patch M cells and oral vaccine targeting. Drug Discov Today, 2005;10: 1145-57. (Pubitemid 41334666)
8. Burns DL, Kenimer JG, Manclark CR. Role of the A subunit of pertussis toxin in alteration of Chinese hamster ovary cell morphology. Infect Immun, 1987;55: 24-8. (Pubitemid 17220362)
9. Chen Y, Mohanraj V, Parkin J. Chitosan-dextran sulfate nanoparticles for delivery of an anti-angiogenesis peptide. Int J Pept Res Ther, 2003;10: 621-9. (Pubitemid 40379055)
10. Chen Y, Mohanraj VJ, Wang F, Benson HA. Designing chitosan-dextran sulfate nanoparticles using charge ratios. AAPS PharmSciTech, 2007;8:E98.
11. Chen Y, Siddalingappa B, Chan PH, Benson HA. Development of a chitosan- based nanoparticle formulation for delivery of a hydrophilic hexapeptide, dalargin. Biopolymers, 2008;90: 663-70.
12. Corbel MJ, Xing DK. Toxicity and potency evaluation of pertussis vaccines. Expert Rev Vaccines, 2004;3: 89-101. (Pubitemid 38196957)
13. Corthesy B. Roundtrip ticket for secretory IgA: Role in mucosal homeostasis? J Immunol, 2007;178: 27-32. (Pubitemid 46033584)
14. Davis SS. Nasal vaccines. Adv Drug Delivery Rev, 2001;51: 21-42. (Pubitemid 32763070)
15. Drogoz A, David L, Rochas C, Domard A, Delair T. Polyelectrolyte complexes from polysaccharides: Formation and stoichiometry monitoring. Langmuir, 2007;23: 10950-8. (Pubitemid 350069311)
16. Favre L, Spertini F, Corthesy B. Secretory IgA possesses intrinsic modulatory properties stimulating mucosal and systemic immune responses. J Immunol, 2005;175: 2793-800. (Pubitemid 41170495)
17. Fowler S, Byron O, Jumel K, Xing D, Corbel MJ, Bolgiano B. Novel configurations of high molecular weight species of the pertussis toxin vaccine component. Vaccine, 2003;21: 2678-88. (Pubitemid 36561361)
18. Fujimura Y, Akisada T, Harada T, Haruma K. Uptake of microparticles into the epithelium of human nasopharyngeal lymphoid tissue. Med Mol Morphol, 2006;39: 181-6. (Pubitemid 46013055)
19. Gan Q, Wang T, Cochrane C, Mccarron P. Modulation of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery. Colloids Surf B: Biointerfaces, 2005;44: 65-73. (Pubitemid 41111534)
20. Hewlett EL, Sauer KT, Myers GA, Cowell JL, Guerrant RL. Induction of a novel morphological response in Chinese hamster ovary cells by pertussis toxin. Infect Immun, 1983;40: 1198-203. (Pubitemid 13103175)
21. Ibsen PH. The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies. Vaccine, 1996;14: 359-68. (Pubitemid 26151870)
22. Illum L. Nanoparticulate systems for nasal delivery of drugs: A real improvement over simple systems? J Pharm Sci, 2007;96: 473-83. (Pubitemid 46466073)
23. Jaganathan KS, Vyas SP. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine, 2006;24: 4201-11.
24. Janes KA, Calvo P, Alonso MJ. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliv Rev, 2001;47: 83-97. (Pubitemid 32209234)
25. Kabanov VA, Zezin AB. A new class of complex water-soluble polyelectrolytes. Die Makromol Chem, 1984;6: 259-76.
26. Kallenius G, Pawlowski A, Brandtzaeg P, Svenson S. Should a new tuberculosis vaccine be administered intranasally? Tuberculosis, 2007;87: 257-66. (Pubitemid 46936239)
27. Kato T. A study of secretory immunoglobulin A on membranous epithelial cells (M cells) and adjacent absorptive cells of rabbit Peyer's patches. Gastroenterol Jpn, 1990;25: 15-23. (Pubitemid 20104369)
28. Kiyono H, Fukuyama S. NALT-versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol, 2004;4: 699-710. (Pubitemid 39223076)
29. Ma Z, Yeoh HH, Lim LY. Formulation pH modulates the interaction of insulin with chitosan nanoparticles. J Pharm Sci, 2002;91: 1396-404. (Pubitemid 34633955)
30. Mantis NJ, Cheung MC, Chintalacharuvu KR, Rey J, Corthesy B, Neutra MR. Selective adherence of IgA to murine Peyer's patch M cells: Evidence for a novel IgA receptor. J Immunol, 2002;169: 1844-51. (Pubitemid 34857646)
31. Mestecky J, Blumberg RS, Kiyono H, Mcghee Jr. 2003. The mucosal immune system. In: Paul WE, ed. Fundamental immunology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins, pp. 965-1020.
32. Mincheva R, Bougard F, Paneva D, Vachaudez M, Manolova N, Rashkov I, Dubois P. Natural polyampholyte-based core-shell nanoparticles with N-carboxyethylchitosan-containing core and poly(ethylene oxide) shell. Biomacromolecules, 2009;10: 838-44.
33. Munoz JJ, Arai H, Cole RL. Mouse-protecting and histamine-sensitizing activities of pertussigen and fimbrial hemagglutinin from Bordetella pertussis. Infect Immun, 1981;32: 243-50. (Pubitemid 11156929)
34. Nencioni L, Pizza MG, Volpini G, de Magistris MT, Giovannoni F, Rappuoli R. Properties of the B oligomer of pertussis toxin. Infect Immun, 1991;59: 4732-4.
35. Nochi T, Yuki Y, Matsumura A, Mejima M, Terahara K, Kim DY, Fukuyama S, Iwatsuki-Horimoto K, Kawaoka Y, Kohda T, et al. A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses. J Exp Med, 2007;204: 2789-96. (Pubitemid 350179549)
36. Pan Y, Li YJ, Zhao HY, Zheng JM, Xu H, Wei G, Hao JS, Cui FD. Bioadhesive polysaccharide in protein delivery system: Chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm, 2002;249: 139-47. (Pubitemid 35333440)
37. Rabilloud T, Brodard V, Peltre G, Righetti PG, Ettori C. Modified silver staining for immobilized pH gradients. Electrophoresis, 1992;13: 264-6.
38. Reddy ST, Swartz MA, Hubbell JA. Targeting dendritic cells with biomaterials: Developing the next generation of vaccines. Trends Immunol, 2006;27: 573-9. (Pubitemid 44708833)
39. Roy MJ, Varvayanis M. Development of dome epithelium in gut-associated lymphoid tissues: Association of IgA with M cells. Cell Tissue Res, 1987;248: 645-51.
40. Sarmento B, Ribeiro A, Veiga F, Ferreira D. Development and characterization of new insulin containing polysaccharide nanoparticles. Colloids Surf B: Biointerfaces, 2006;53: 193-202. (Pubitemid 44802985)
41. Schatz C, Lucas JM, Viton C, Domard A, Pichot C, Delair T. Formation and properties of positively charged colloids based on polyelectrolyte complexes of biopolymers. Langmuir, 2004;20: 7766-78.
42. Sharma S, Mukkur TK, Benson HA, Chen Y. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J Pharm Sci, 2009;98: 812-43.
43. Sogias IA, Williams AC, Khutoryanskiy VV. Why is chitosan mucoadhesive?. Biomacromolecules, 2008;9: 1837-42.
44. Tiyaboonchai W, Limpeanchob N. Formulation and characterization of amphotericin B-chitosan-dextran sulfate nanoparticles. Int J Pharm, 2007;329: 142-9. (Pubitemid 44937518)
45. WHO. 2005. Pertussis vaccines WHO position paper. Weekly epidemiological record. Geneva: World Health Organization.
46. Xu Y, Du Y. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int J Pharm, 2003;250: 215-26. (Pubitemid 35447951)
47. Zhou F, Kraehenbuhl JP, Neutra MR. Mucosal IgA response to rectally administered antigen formulated in IgA-coated liposomes. Vaccine, 1995;13: 637-44.